

Prostate Cancer Drugs-Asia Pacific Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/P771DF9E3F0MEN.html>

Date: February 2018

Pages: 142

Price: US\$ 3,480.00 (Single User License)

ID: P771DF9E3F0MEN

Abstracts

Report Summary

Prostate Cancer Drugs-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Prostate Cancer Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Asia Pacific and Regional Market Size of Prostate Cancer Drugs 2013-2017, and development forecast 2018-2023

Main market players of Prostate Cancer Drugs in Asia Pacific, with company and product introduction, position in the Prostate Cancer Drugs market

Market status and development trend of Prostate Cancer Drugs by types and applications

Cost and profit status of Prostate Cancer Drugs, and marketing status

Market growth drivers and challenges

The report segments the Asia Pacific Prostate Cancer Drugs market as:

Asia Pacific Prostate Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

China

Japan

Korea

India

Southeast Asia

Australia

Asia Pacific Prostate Cancer Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Hormonal Therapy

Chemotherapy

Immunotherapy

Targeted Therapy

Asia Pacific Prostate Cancer Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinics

Hospitals

Other

Asia Pacific Prostate Cancer Drugs Market: Players Segment Analysis (Company and Product introduction, Prostate Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):

AbbVie

Astellas Pharma

Astra Zeneca

Johnson & Johnson

Sanofi

GlaxoSmithKline

Merck Group

Novartis

Amgen

Bayer HealthCare

Ferring Pharmaceutical

Janssen Pharmaceuticals

Endo Pharmaceuticals

BMS

Takeda Pharmaceuticals

Northwest Biotherapeutics

Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PROSTATE CANCER DRUGS

- 1.1 Definition of Prostate Cancer Drugs in This Report
- 1.2 Commercial Types of Prostate Cancer Drugs
 - 1.2.1 Hormonal Therapy
 - 1.2.2 Chemotherapy
 - 1.2.3 Immunotherapy
 - 1.2.4 Targeted Therapy
- 1.3 Downstream Application of Prostate Cancer Drugs
 - 1.3.1 Clinics
 - 1.3.2 Hospitals
 - 1.3.3 Other
- 1.4 Development History of Prostate Cancer Drugs
- 1.5 Market Status and Trend of Prostate Cancer Drugs 2013-2023
 - 1.5.1 Asia Pacific Prostate Cancer Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Prostate Cancer Drugs Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Prostate Cancer Drugs in Asia Pacific 2013-2017
- 2.2 Consumption Market of Prostate Cancer Drugs in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of Prostate Cancer Drugs in Asia Pacific by Regions
 - 2.2.2 Revenue of Prostate Cancer Drugs in Asia Pacific by Regions
- 2.3 Market Analysis of Prostate Cancer Drugs in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Prostate Cancer Drugs in China 2013-2017
 - 2.3.2 Market Analysis of Prostate Cancer Drugs in Japan 2013-2017
 - 2.3.3 Market Analysis of Prostate Cancer Drugs in Korea 2013-2017
 - 2.3.4 Market Analysis of Prostate Cancer Drugs in India 2013-2017
 - 2.3.5 Market Analysis of Prostate Cancer Drugs in Southeast Asia 2013-2017
 - 2.3.6 Market Analysis of Prostate Cancer Drugs in Australia 2013-2017
- 2.4 Market Development Forecast of Prostate Cancer Drugs in Asia Pacific 2018-2023
 - 2.4.1 Market Development Forecast of Prostate Cancer Drugs in Asia Pacific 2018-2023
 - 2.4.2 Market Development Forecast of Prostate Cancer Drugs by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Asia Pacific Market Status by Types
 - 3.1.1 Consumption Volume of Prostate Cancer Drugs in Asia Pacific by Types
 - 3.1.2 Revenue of Prostate Cancer Drugs in Asia Pacific by Types
- 3.2 Asia Pacific Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in China
 - 3.2.2 Market Status by Types in Japan
 - 3.2.3 Market Status by Types in Korea
 - 3.2.4 Market Status by Types in India
 - 3.2.5 Market Status by Types in Southeast Asia
 - 3.2.6 Market Status by Types in Australia
- 3.3 Market Forecast of Prostate Cancer Drugs in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Prostate Cancer Drugs in Asia Pacific by Downstream Industry
- 4.2 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Prostate Cancer Drugs by Downstream Industry in China
 - 4.2.2 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Japan
 - 4.2.3 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Korea
 - 4.2.4 Demand Volume of Prostate Cancer Drugs by Downstream Industry in India
 - 4.2.5 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Southeast Asia
 - 4.2.6 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Australia
- 4.3 Market Forecast of Prostate Cancer Drugs in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROSTATE CANCER DRUGS

- 5.1 Asia Pacific Economy Situation and Trend Overview
- 5.2 Prostate Cancer Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 PROSTATE CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

- 6.1 Sales Volume of Prostate Cancer Drugs in Asia Pacific by Major Players
- 6.2 Revenue of Prostate Cancer Drugs in Asia Pacific by Major Players
- 6.3 Basic Information of Prostate Cancer Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Prostate Cancer Drugs Major Players

6.3.2 Employees and Revenue Level of Prostate Cancer Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 PROSTATE CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AbbVie

7.1.1 Company profile

7.1.2 Representative Prostate Cancer Drugs Product

7.1.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of AbbVie

7.2 Astellas Pharma

7.2.1 Company profile

7.2.2 Representative Prostate Cancer Drugs Product

7.2.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas

Pharma

7.3 Astra Zeneca

7.3.1 Company profile

7.3.2 Representative Prostate Cancer Drugs Product

7.3.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astra Zeneca

7.4 Johnson & Johnson

7.4.1 Company profile

7.4.2 Representative Prostate Cancer Drugs Product

7.4.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson &

Johnson

7.5 Sanofi

7.5.1 Company profile

7.5.2 Representative Prostate Cancer Drugs Product

7.5.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi

7.6 GlaxoSmithKline

7.6.1 Company profile

7.6.2 Representative Prostate Cancer Drugs Product

7.6.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of

GlaxoSmithKline

7.7 Merck Group

- 7.7.1 Company profile
- 7.7.2 Representative Prostate Cancer Drugs Product
- 7.7.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Merck Group
- 7.8 Novartis
 - 7.8.1 Company profile
 - 7.8.2 Representative Prostate Cancer Drugs Product
 - 7.8.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.9 Amgen
 - 7.9.1 Company profile
 - 7.9.2 Representative Prostate Cancer Drugs Product
 - 7.9.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen
- 7.10 Bayer HealthCare
 - 7.10.1 Company profile
 - 7.10.2 Representative Prostate Cancer Drugs Product
 - 7.10.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
- 7.11 Ferring Pharmaceutical
 - 7.11.1 Company profile
 - 7.11.2 Representative Prostate Cancer Drugs Product
 - 7.11.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceutical
- 7.12 Janssen Pharmaceuticals
 - 7.12.1 Company profile
 - 7.12.2 Representative Prostate Cancer Drugs Product
 - 7.12.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Janssen Pharmaceuticals
- 7.13 Endo Pharmaceuticals
 - 7.13.1 Company profile
 - 7.13.2 Representative Prostate Cancer Drugs Product
 - 7.13.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
- 7.14 BMS
 - 7.14.1 Company profile
 - 7.14.2 Representative Prostate Cancer Drugs Product
 - 7.14.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of BMS
- 7.15 Takeda Pharmaceuticals
 - 7.15.1 Company profile
 - 7.15.2 Representative Prostate Cancer Drugs Product
 - 7.15.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Takeda

Pharmaceuticals

7.16 Northwest Biotherapeutics

7.17 Teva Pharmaceutical

7.18 Boehringer Ingelheim

7.19 Foresee Pharmaceuticals

7.20 Tokai Pharmaceuticals

7.21 Spectrum Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROSTATE CANCER DRUGS

8.1 Industry Chain of Prostate Cancer Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROSTATE CANCER DRUGS

9.1 Cost Structure Analysis of Prostate Cancer Drugs

9.2 Raw Materials Cost Analysis of Prostate Cancer Drugs

9.3 Labor Cost Analysis of Prostate Cancer Drugs

9.4 Manufacturing Expenses Analysis of Prostate Cancer Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF PROSTATE CANCER DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Prostate Cancer Drugs-Asia Pacific Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/P771DF9E3F0MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P771DF9E3F0MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970